BGI Genomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

BGI Genomics hat ein Gesamteigenkapital von CN¥10.0B und eine Gesamtverschuldung von CN¥347.5M, was einen Verschuldungsgrad von 3.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CN¥13.3B bzw. CN¥3.3B.

Wichtige Informationen

3.5%

Verhältnis von Schulden zu Eigenkapital

CN¥347.54m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CN¥4.71b
Eigenkapital	CN¥9.97b
Gesamtverbindlichkeiten	CN¥3.31b
Gesamtvermögen	CN¥13.28b

Jüngste Berichte zur Finanzlage

Recent updates

Is BGI Genomics (SZSE:300676) Using Too Much Debt?

Oct 22

BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%

Oct 01

Is BGI Genomics (SZSE:300676) A Risky Investment?

Jul 15

Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S

May 22

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Apr 21

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Mar 25

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 300676Die kurzfristigen Aktiva des Unternehmens (CN¥7.6B) übersteigen seine kurzfristigen Passiva (CN¥2.9B).

Langfristige Verbindlichkeiten: 300676Die kurzfristigen Vermögenswerte des Unternehmens (CN¥7.6B) übersteigen seine langfristigen Verbindlichkeiten (CN¥436.6M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 300676 über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: 300676Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 3.5% gestiegen.

Schuldendeckung: 300676Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (24.1%).

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von 300676 für seine Schulden durch das EBIT gut gedeckt sind.

BGI Genomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is BGI Genomics (SZSE:300676) Using Too Much Debt?

Is BGI Genomics (SZSE:300676) A Risky Investment?

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Recent updates

Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023)

Is BGI Genomics (SZSE:300676) Using Too Much Debt?

BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%

BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023)

High number of new directors

Is BGI Genomics (SZSE:300676) A Risky Investment?

BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024

BGI Genomics Co., Ltd. Announces Board Appointments

Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S

Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.091 in 1Q 2023)

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024

BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022)

BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022)

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022)

BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023

First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022)

Investor sentiment improves as stock rises 30%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021)

BGI Genomics Announces Final Profit Distribution for 2021 payable on 06 July 2022

BGI Genomics Co., Ltd. Approves Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020)

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Chairman of Scientific Advisory Board Tadataka Yamada has left the company

Investor sentiment improved over the past week

BGI Genomics Co., Ltd. (SZSE:300676) completed the acquisition of remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd.

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

BGI Genomics Co., Ltd. Approves Cash Dividend for 2020

BGI Genomics Co., Ltd. (SZSE:300676) agreed to acquire the remaining 1% stake in Beijing BGI Medical Laboratory Co., Ltd. from Beijing BGI Research Centre Co., Ltd. for CNY 2.37 million.

BGI Genomics Co., Ltd. Announces Final Cash Dividend Proposal for 2020

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020)

New 90-day low: CN¥125

Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019)

Revenue and earnings miss expectations

Investor sentiment deteriorated over the past week

New 90-day high: CN¥166

Investor sentiment improved over the past week

New 90-day low: CN¥127

New 90-day low: CN¥133

Third quarter earnings released

New 90-day low: CN¥133

First half earnings released

BGI Genomics Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

BGI Genomics Co., Ltd. announced that it expects to receive CNY 2.0119372 billion in funding

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen